---
title: "Novo Nordisk's weekly injection diabetes drug Kyinsu has been approved in the European Union"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/258084794.md"
description: "Novo Nordisk's weekly injectable diabetes medication has been approved by the European Union, providing patients with another treatment option. The European Medicines Agency's drug review panel recommended the approval of Kyinsu for the treatment of patients with type 2 diabetes. This combination injectable, consisting of insulin and semaglutide (the active ingredient in Novo Nordisk's bestselling weight loss drug Ozempic), is also known as IcoSema. Trials of the drug have shown that it helps patients with type 2 diabetes better control their weight and lower blood sugar, outperforming daily insulin injections. This medication is also beneficial for those who cannot control their diabetes through daily insulin injections. The long-acting insulin component of the drug was previously rejected for approval by the U.S. Food and Drug Administration, as the agency requested more detailed information regarding the manufacturing process and indications for type 1 diabetes"
datetime: "2025-09-19T11:48:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258084794.md)
  - [en](https://longbridge.com/en/news/258084794.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258084794.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/258084794.md) | [English](https://longbridge.com/en/news/258084794.md)


# Novo Nordisk's weekly injection diabetes drug Kyinsu has been approved in the European Union

According to Zhitong Finance APP, Novo Nordisk (NVO.US) has received EU approval for a diabetes medication that is injected once a week, providing patients with another treatment option. The European Medicines Agency's drug review panel has recommended the approval of Kyinsu for the treatment of patients with type 2 diabetes. This combination injection, consisting of insulin and semaglutide (the active ingredient in Novo Nordisk's bestselling weight loss drug Ozempic), is also known as IcoSema.

Trials of the drug have shown that it helps patients with type 2 diabetes better control their weight and lower blood sugar levels, outperforming daily insulin injections. It is also beneficial for those who cannot manage their diabetes through daily insulin injections.

The long-acting insulin component of the drug was previously rejected for approval by the U.S. Food and Drug Administration, as the agency requested more detailed information regarding the manufacturing process and indications for type 1 diabetes

### 相關股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-HK/quote/NVO.US.md)

## 相關資訊與研究

- [As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?](https://longbridge.com/zh-HK/news/270794581.md)
- [LIVE MARKETS-Does a Good Friday jobs report = a rocky ride on Monday?](https://longbridge.com/zh-HK/news/281558023.md)
- [Trump speech unleashes more pain on US consumers with $5 gasoline, record diesel in sight](https://longbridge.com/zh-HK/news/281550771.md)
- [SpaceX Valuation at $2 Trillion: How It Surpasses Meta and Tesla?](https://longbridge.com/zh-HK/news/281611627.md)
- [PREVIEW-Samsung Elec likely to report stupendous surge in quarterly profit to record level](https://longbridge.com/zh-HK/news/281616659.md)